Biochemical and pharmacologic comparison of thrombolytic agents.
The number of thrombolytic drugs for the management of acute myocardial infarction is rapidly expanding. New agents, some of which are biochemically modified versions of currently available thrombolytics, will soon arrive in the marketplace. The pharmacologic differences of the new drugs are the basis for clinical differences such as enhanced clot lysis and prolonged elimination half-life. Ultimately, these features may result in improved infarct artery patency and patient survival.
Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA.
K A
KA
Stringer
D000595:Amino Acid Sequence; D016255:Anistreplase / Q000737:chemistry / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008969:Molecular Sequence Data; D009203:Myocardial Infarction / Q000188:drug therapy*; D010960:Plasminogen Activators / Q000737:chemistry / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000737:chemistry / Q000627:therapeutic use; D013300:Streptokinase / Q000737:chemistry / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D016255:Anistreplase; C087896:reteplase; D013300:Streptokinase; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator